Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 379.7 DKK -1.89% Market Closed
Market Cap: 27B DKK

Wall Street
Price Targets

ZEAL Price Targets Summary
Zealand Pharma A/S

Wall Street analysts forecast ZEAL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZEAL is 927.44 DKK with a low forecast of 489.85 DKK and a high forecast of 1 176 DKK.

Lowest
Price Target
489.85 DKK
29% Upside
Average
Price Target
927.44 DKK
144% Upside
Highest
Price Target
1 176 DKK
210% Upside
Zealand Pharma A/S Competitors:
Price Targets
TSHA
Taysha Gene Therapies Inc
226% Upside
VIR
Vir Biotechnology Inc
259% Upside
AZT
Arcticzymes Technologies ASA
9% Upside
FYB
Formycon AG
114% Upside
6955
Shandong Boan Biotechnology Co Ltd
16% Downside
BMRN
Biomarin Pharmaceutical Inc
78% Upside
IKT
Inhibikase Therapeutics Inc
392% Upside
BEAM
Beam Therapeutics Inc
169% Upside

Revenue
Forecast

Revenue Estimate
Zealand Pharma A/S

For the last 8 years the compound annual growth rate for Zealand Pharma A/S's revenue is -15%. The projected CAGR for the next 3 years is 205%.

-15%
Past Growth
205%
Estimated Growth
Estimates Accuracy
-23%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Zealand Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Net Income
Forecast

Net Income Estimate
Zealand Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-33%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ZEAL's stock price target?
Price Target
927.44 DKK

According to Wall Street analysts, the average 1-year price target for ZEAL is 927.44 DKK with a low forecast of 489.85 DKK and a high forecast of 1 176 DKK.

What is Zealand Pharma A/S's Revenue forecast?
Projected CAGR
205%

For the last 8 years the compound annual growth rate for Zealand Pharma A/S's revenue is -15%. The projected CAGR for the next 3 years is 205%.

Back to Top